CAESAREA, Israel--(BUSINESS WIRE)--Itamar (TASE:ITMR) announced today that it signed an agreement with Roche (SIX:RO, ROG; OTCQX:RHHBY) for use of Itamar’s EndoPAT device in a clinical phase II study for patients with Peripheral Arterial Disease (PAD) at 80 worldwide medical centers. The assessment of endothelial function by EndoPAT will provide one endpoint of the study that will test the effectiveness of a newly developed drug.
The agreement is valued at approximately $2.7M to be paid in installments through the study period that is scheduled to last until Dec. 2012.
“We are very excited to work with Roche in this study that reinforces our strategic direction whereby EndoPAT plays a major role within the pharmaceutical industry of personalized medicine and companion diagnostics,” said Dr. Dov Rubin, Itamar-Medical’s President and CEO.
“EndoPAT offers the only non-invasive technology that is FDA-indicated for detecting endothelial dysfunction which is easily applied and totally operator independent,” said Dr. Koby Sheffy, Itamar-Medical’s CTO and Sr. Vice President. “With more than 80 papers to date in peer-reviewed journals and over 100 abstracts at major scientific meetings, we feel EndoPAT is well positioned as a clinically valid procedure.”
Itamar-Medical is the developer of EndoPAT, which diagnoses endothelial dysfunction - an important state in the development and progress of atherosclerosis affecting both early and late stage of the disease. EndoPAT has now been deployed by over 10 pharmaceutical companies, many of which are among the Fortune 100, in nearly 20 different large-scale drug development studies and has been proven to both shorten the time, and reduce the cost, of drug development.
About Itamar Medical
Itamar Medical Ltd. is a publicly-traded medical technology company utilizing PAT™ (Peripheral Arterial Tone) signal technology and applications. The PAT signal is a non-invasive “window” to both the cardiovascular and autonomic nervous systems. For more information, visit www.itamar-medical.com.
Contact:
Triwaks Public Relations Daphna Triwaks, 972-50-5202322 daphna@triwaks.co.il
